Related Experiment Video
Updated: Mar 3, 2026
11:58
A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers
Published on: August 21, 2021
6.0K
Resistant starch suppresses postprandial hypertriglyceridemia in rats
Hiroko Matsuda1, Kodai Kumazaki1, Ryo Otokozawa1
1Laboratory of Salad Science, Graduate School of Marine Science and Technology, Tokyo University of Marine Science and Technology, Tokyo 108-8477, Japan.
Food Research International (Ottawa, Ont.)
|May 3, 2017
Summary
Dietary resistant starch (RS) intake with fats significantly reduces postprandial triglyceride levels. This suggests RS may help prevent coronary artery disease by inhibiting fat absorption and promoting excretion.
Area of Science:
- Nutrition Science
- Gastroenterology
- Cardiovascular Health
Background:
- Postprandial hypertriglyceridemia is a risk factor for coronary artery disease.
- Dietary resistant starch (RS) shows promise for disease prevention, impacting glycemic control, diabetes, cholesterol, and weight.
- The specific effects of daily RS intake on postprandial hypertriglyceridemia require further investigation.
Purpose of the Study:
- To investigate the impact of a single dose of cornstarch-derived RS on postprandial triglyceride levels.
- To assess RS's effect on dietary fat absorption and excretion.
Main Methods:
- Oral fat tolerance tests were conducted in rats.
- Serum triglyceride levels were measured after lipid meals with and without RS.
- Fecal lipid content and wet weight were analyzed.
Main Results:
- RS administration significantly reduced postprandial increases in serum triglycerides.
- Fecal lipid volume and wet weight were significantly higher in rats consuming RS with lipid meals, indicating inhibited fat absorption.
- A positive correlation was found between fecal lipid content and wet weight.
Conclusions:
- Once-daily intake of RS with dietary fats effectively reduces postprandial hypertriglyceridemia.
- RS inhibits dietary fat absorption, leading to increased fecal lipid excretion.
- These findings support the health-promoting potential of RS in managing cardiovascular risk factors.
Keywords:
Chenodeoxycholic acid (PubChem CID: 10133)Cholic acid (PubChem CID: 221493)Citric acid (PubChem CID: 311)Deoxycholic acid (PubChem CID: 222528)Ethanol (PubChem CID: 702)Lipase (PubChem CID: 54603431)Oral fat tolerance/loading testPostprandial hypertriglyceridemiaResistant starchTaurocholic acid (PubChem CID: 6675)
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
684
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
684
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
787
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
787